1. A thermoplastic resin, having a main chain structure comprising:
a unit (A) by 25 mol % to 60 mol %, the unit (A) having a biphenyl group and being represented by general formula (1):
wherein X represents a bivalent substituent selected from the group consisting of O and CO;
a unit (B) by 25 mol % to 60 mol %, the unit (B) being represented by general formula (2):
-Y-R-Y-\u2003\u2003(2)
wherein R represents a bivalent linear substituent (a) whose number of atoms in its main chain length is 2 to 20 and (b) which is branched or not branched, and Y represents a bivalent substituent selected from the group consisting of O and CO; and
a unit (C) by 1 mol % to 25 mol %, the unit (C) being represented by general formula (3):
-Z1-A-Z2-\u2003\u2003(3)
wherein Z1 and Z2 represent a bivalent substituent(s) selected from the group consisting of O, NH, CO, S, and NHCO, and A represents a substituent selected from the group consisting of non-fused aromatic groups, fused aromatic groups, heterocyclic groups, alicyclic groups, and alicyclic heterocyclic groups, each of which has an effect of folding a main chain,
where a total amount of the units (A), (B), and (C) is 100 mol %.
2. The thermoplastic resin as set forth in claim 1, wherein X in the general formula (1) is O and Y in the general formula (2) is CO.
3. The thermoplastic resin as set forth in claim 1, wherein R of the thermoplastic resin is a linear aliphatic hydrocarbon chain.
4. The thermoplastic resin as set forth in claim 1, wherein R of the thermoplastic resin has a main chain length of an even number.
5. The thermoplastic resin as set forth in claim 1, wherein R of the thermoplastic resin is at least one selected from the group consisting of \u2014(CH2)8\u2014, \u2014(CH2)10\u2014, and \u2014(CH2)12\u2014.
6. The thermoplastic resin as set forth in claim 1, wherein A of the thermoplastic resin is any one of structures shown below.
7. The thermoplastic resin as set forth in claim 1, wherein the thermoplastic resin has a number average molecular weight of 3000 to 40000.
8. The thermoplastic resin as set forth in claim 1, wherein not less than 60 mol % of polymer chain ends are carboxyl groups.
9. The thermoplastic resin as set forth in claim 1, wherein the thermoplastic resin contains a lamellar crystal by not less than 10 vol %.
10. The thermoplastic resin as set forth in claim 1, wherein a thermal conductivity of the thermoplastic resin itself is not less than 0.6 W(m\xb7K).
11. A thermoplastic resin composition comprising:
a thermoplastic resin as set forth in claim 1; and
an inorganic filler.
12. The thermoplastic resin composition as set forth in claim 11, wherein the inorganic filler is an inorganic compound having a thermal conductivity of not less than 1 W(m\xb7K) by itself.
13. The thermoplastic resin composition as set forth in claim 11, wherein the inorganic filler is one or more electrically-insulative highly thermally conductive inorganic compounds selected from the group consisting of boron nitride, aluminum nitride, silicon nitride, aluminum oxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, magnesium hydrate, beryllium oxide, and diamond.
14. The thermoplastic resin composition as set forth in claim 11, wherein the inorganic filler is one or more electrically-conductive highly thermally conductive inorganic compounds selected from the group consisting of graphite, electrically-conductive metal powder, soft magnetism ferrite, carbon fiber, electrically-conductive metal fiber, and zinc oxide.
15. A molded member produced from a thermoplastic resin composition as set forth in claim 11.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound according to the formula:
or a salt thereof, wherein:
R2 is selected from phenyl mono-substituted at the 3- or 5-position with an R8 group and phenyl di- or tri-substituted with the same or different R8 groups;
R4 is phenyl substituted with one or more of the same or different R8 groups;
R5 is halogen;
R6 is hydrogen;
R8 is selected from the group consisting of Ra, Rb, Ra substituted with one or more of the same or different Ra or Rb, \u2014ORa substituted with one or more of the same or different Ra or Rb, \u2014B(ORa)2, \u2014B(NRcRc)2, \u2014(CH2)m\u2014Rb, \u2014(CHRa)m\u2014Rb, \u2014O\u2014(CH2)m\u2014Rb, \u2014S\u2014(CH2)m\u2014Rb, \u2014O\u2014CHRaRb, \u2014O\u2014CRa(Rb)2, \u2014O\u2014(CHRa)m\u2014Rb, \u2014O\u2014(CH2)m\u2014CH(CH2)mRbRb, \u2014S\u2014(CHRa)m\u2014Rb, \u2014C(O)NH\u2014(CH2)m\u2014Rb, \u2014C(O)NH\u2014(CHRa)m\u2014Rb, \u2014O\u2014(CH2)m\u2014C(O)NH\u2014(CH2)m\u2014Rb, \u2014S\u2014(CH2)m\u2014C(O)NH\u2014(CH2)m\u2014Rb, \u2014O\u2014(CHRa)m\u2014C(O)NH\u2014(CHRa)m\u2014Rb, \u2014S\u2014(CHRa)m\u2014C(O)NH\u2014(CHRa)m\u2014Rb, \u2014NH\u2014(CH2)m\u2014Rb, \u2014NH\u2014(CHRa)m\u2014Rb, \u2014NH(CH2)mRb, \u2014N(CH2)mRb2, \u2014NH\u2014C(O)\u2014NH\u2014(CH2)m\u2014Rb, \u2014NH\u2014C(O)\u2014(CH2)m\u2014CHRbRb and \u2014NH\u2014(CH2)m\u2014C(O)\u2014NH\u2014(CH2)m\u2014Rb;
each Ra is independently selected from the group consisting of (C1-C6) alkyl, (C3-C8)cycloalkyl, cyclohexyl, (C4-C11)cycloalkylalkyl, (C5-C10)aryl, phenyl, (C6-C16)arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl and 6-16 membered heteroarylalkyl;
each Rb is a suitable group independently selected from the group consisting of \u2550O, \u2014ORd, \u2014OH, (C1-C3)haloalkyloxy, \u2014OCF3, \u2550S, \u2014SRd, \u2550NRd, \u2550NORd, \u2014NRcRc, halogen, \u2014CF3, \u2014NC, \u2014OCN, \u2014SCN, \u2014NO, \u2014NO2, \u2550N2, \u2014N3, \u2014S(O)Rd, \u2014S(O)2Rd, \u2014S(O)2ORd, \u2014S(O)NRcRc, \u2014S(O)2NRcRc, OS(O)Rd, \u2014OS(O)2Rd, \u2014OS(O)2ORd, OS(O)2NRcRc, \u2014C(O)Rd, \u2014C(O)ORd, \u2014C(O)NRcRc, \u2014C(NH)NRcRc, \u2014C(NRa)NRcRc, \u2014C(NOH)Ra, \u2014C(NOH)NRcRc, \u2014OC(O)Rd, \u2014OC(O)ORd, \u2014OC(O)NRcRc, \u2014OC(NH)NRcRc, \u2014OC(NRa)NRcRc, \u2014NHC(O)nRd, \u2014NRaC(O)nRd, \u2014NHC(O)nORd, \u2014NRaC(O)nORd, \u2014NHC(O)nNRcRc, \u2014NRaC(O)nNRcRc, \u2014NHC(NH)nNRcRc and \u2014NRaC(NRa)nNRcRc;
each Rc is independently a protecting group or Ra, or, alternatively, each Rc is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different Ra or suitable Rb groups;
each Rd is independently a protecting group or Ra;
each m is independently an integer from 1 to 3; and
each n is independently an integer from 0 to 3, with the provisos that:
(1) R2 is not 3,4,5-tri (C1-C6)alkoxyphenyl; and
(2) the compound is not
N2,N4-bis(3-methylphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(3-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(2,5-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(3,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(2,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(3-bromophenyl)-5-fluoro-2,4-pyrimidinediamine;
N2,N4-bis(3-chloro-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; or
N2,N4-Bis(3-chloro-4-methoxy)-5-fluoro-2,4-pyrimidinediamine.
2. The compound of claim 1, wherein R2 is phenyl di-substituted with the same or different R8 groups.
3. The compound of claim 2, wherein R2 is 3,4-substituted.
4. The compound of claim 1, wherein R4 is mono-substituted with an R8 group.
5. The compound of claim 4, wherein R4 is para-substituted with the R8 group.
6. The compound of claim 1, wherein R5 is fluoro.
7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
8. The composition of claim 7, wherein the compound is in the form of a pharmaceutically acceptable salt.
9. A method for treating a subject suffering from a disease or condition mediated by the regulation or inhibition of Syk kinase, wherein the disease or condition is selected from the group consisting of scleroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury, post myocardial infarction, chronic obstructive pulmonary disease, cardiobronchitis, post myocardial infarction, osteoarthritis, ulcerative colitis, Crohn’s disease, idiopathic inflammatory bowel disease, irritable bowel syndrome, spastic colon, inflammatory bowel disease, inflammation, and scarring, the method comprising administering to the subject an effective amount of a compound according to claim 1.
10. A method for treating a subject suffering from an allergic disease or condition mediated by the regulation or inhibition of Syk kinase, wherein the allergic disease or condition is selected from the group consisting of conjunctivitis, rhinitis, asthma, atopic dermatitis and food allergies, the method comprising administering to the subject an effective amount of a compound according to claim 1.
11. The compound according to claim 1 wherein the phenyl of R2 or R4 is trisubstituted at the 3, 4, and 5 positions.